IL-17 Enhances the Net Angiogenic Activity and In Vivo Growth of Human Non-Small Cell Lung Cancer in SCID Mice through Promoting CXCR-2-Dependent Angiogenesis

Department of Geriatric and Respiratory Medicine, Tohoku University School of Medicine, Sendai, Japan.
The Journal of Immunology (Impact Factor: 4.92). 12/2005; 175(9):6177-89. DOI: 10.4049/jimmunol.175.9.6177
Source: PubMed


In this study, we examined the biological action of IL-17 on human non-small cell lung cancer (NSCLC). Although IL-17 had no direct effect on the in vitro growth rate of NSCLC, IL-17 selectively augmented the secretion of an array of angiogenic CXC chemokines, including CXCL1, CXCL5, CXCL6, and CXCL8 but not angiostatic chemokines, by three different NSCLC lines. Endothelial cell chemotactic activity (as a measure of net angiogenic potential) was increased in response to conditioned medium from NSCLC stimulated with IL-17 compared with those from unstimulated NSCLC. Enhanced chemotactic activity was suppressed by neutralizing mAb(s) to CXCL1, CXCL5, and CXCL8 or to CXCR-2 but not to vascular endothelial growth factor-A. Transfection with IL-17 into NSCLC had no effect on the in vitro growth, whereas IL-17 transfectants grew more rapidly compared with controls when transplanted in SCID mice. This IL-17-elicited enhancement of NSCLC growth was associated with increased tumor vascularity. Moreover, treatment with anti-mouse CXCR-2-neutralizing Ab significantly attenuated the growth of both neomycin phosphotransferase gene-transfected and IL-17-transfected NSCLC tumors in SCID mice. A potential role for IL-17 in modulation of the human NSCLC phenotype was supported by the findings that, in primary NSCLC tissues, IL-17 expression was frequently detected in accumulating and infiltrating inflammatory cells and that high levels of IL-17 expression were associated with increased tumor vascularity. These results demonstrate that IL-17 increases the net angiogenic activity and in vivo growth of NSCLC via promoting CXCR-2-dependent angiogenesis and suggest that targeting CXCR-2 signaling may be a novel promising strategy to treat patients with NSCLC.

Download full-text


Available from: Muneo Numasaki,
60 Reads
  • Source
    • "IL-17 is produced from various T-cell subsets such as CD4 + T cells, CD8 + T cells, NKT cells, and γδT cells [29] [30] [31] [32]. Cancer tissues are suggested to express IL-17 [33] [34], and IL-17 promotes cancer angiogenesis resulting in cancer advance [35]. Th2 cytokines produced in cancer microenvironment are suggested to play a role in inhibition of cellular immunity against cancer [36]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Several cytokines secreted from breast cancer tissues are suggested to be related to disease prognosis. We examined Th1/Th2/Th17 cytokines produced from three-dimensionally cultured breast cancer tissues and related them with patient clinical profiles. 21 tumor tissues and 9 normal tissues surgically resected from breast cancer patients were cultured in thermoreversible gelatin polymer-containing medium. Tissue growth and Th1/Th2/Th17 cytokine concentrations in the culture medium were analyzed and were related with hormone receptor expressions and patient clinical profiles. IL-6 and IL-10 were expressed highly in culture medium of both cancer and normal tissues. However, IFN-γ, TNF-α, IL-2, and IL-17A were not detected in the supernatant of the three-dimensionally cultured normal mammary gland and are seemed to be specific to breast cancer tissues. The growth abilities of hormone receptor-negative cancer tissues were significantly higher than those of receptor-positive tissues (P=0.0383). Cancer tissues of stage ≥IIB patients expressed significantly higher TNF-α levels as compared with those of patients with stage <IIB (P=0.0096). The tumor tissues resected from breast cancer patients can grow in the three-dimensional thermoreversible gelatin polymer culture system and produce Th1/Th2/Th17 cytokines. Hormone receptor-positive cancer tissues showed less growth ability. TNF-α is suggested to be a biomarker for the cancer stage. Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.
    Translational oncology 08/2015; 8(4):318-26. DOI:10.1016/j.tranon.2015.06.004 · 2.88 Impact Factor
  • Source
    • "However, the role of IL-17 in tumor immunity remains undefined. Functionally, overexpression of IL-17 in tumor cell lines promotes angiogenesis and tumor growth when the tumors are implanted in immune-compromised mice [85]. Intranasal treatment of mice with a neutralizing anti-IL-17A antibody in experimental lung adenocarcinoma caused a significant reduction of tumor growth as compared to control treated mice [32]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Pathogenic mechanisms underlying the development of lung cancer are very complex and not yet entirely clarified. T lymphocytes and their immune-regulatory cytokines play a pivotal role in controlling tumor growth and metastasis. Following activation by unique cytokines, CD4+ T helper cells differentiate into Th1, Th2, Th17, and regulatory T cells (Tregs). Traditionally, research in lung cancer immunity has focused almost exclusively on Th1/Th2 cell balance. Recently, Th17 cells and Tregs represent an intriguing issue to be addressed in lung cancer pathogenesis. Tregs play an important role in the preservation of self-tolerance and modulation of overall immune responses against tumor cells. Th17 cells directly or via other proinflammatory cytokines modulate antitumor immune responses. Notably, there is a close relation between Tregs and Th17 cells. However, the possible interaction between these subsets in lung cancer remains to be elucidated. In this setting, targeting Treg/Th17 balance for therapeutic purposes may represent a useful tool for lung cancer treatment in the future. The purpose of this review is to discuss recent findings of the role of these novel populations in lung cancer immunity and to highlight the pleiotropic effects of these subsets on the development and regulation of lung cancer.
    Research Journal of Immunology 04/2014; 2014:730380. DOI:10.1155/2014/730380
  • Source
    • "Tartour et al. [39] injected nude mice with human cervical tumor cells transfected with human cDNA encoding IL-17 and found that they grew more quickly than parental tumors. Numasaki et al. [38] demonstrated that human nonsmall cell lung cancer transfected with human IL-17 grew faster in severe combined immunodeficiency (SCID) mice than did control non-small cell lung cancer cells. "
    [Show abstract] [Hide abstract]
    ABSTRACT: CD4+ T helper (Th) cells play an important role in modulating immune responses. Th17 cells are a newly established Th subpopulation. Th17 cells differentiate in the presence of TGF-β and IL-6 in mice or IL-1β and IL-6 in humans, depending on the transcription factor RORγt. IL-23 stabilizes the Th17 cells phenotype and helps Th17 cells acquire effector functions. Th17 secretes IL-17, IL-21, and IL-22, which play significant role in the immune response against viruses, extracellular bacteria and fungi, as well as in the pathogenesis of inflammatory diseases. The systemic and local activity of IL-17 and Th17 seems to be an important part of development of autoimmune reaction. Th17 cell subpopulation has been described in many types of cancer, including gastric cancer, melanoma, breast cancer, and ovarian cancer, but it remains unclear whether Th17 cells promote or inhibit tumor progression and the mechanism of their involvement in tumor immunity is unknown. This review summarizes the current knowledge on the role of Th17 cells in tumor immunity.
    Acta haematologica Polonica 04/2014; 45(2). DOI:10.1016/j.achaem.2014.04.017
Show more